Worldwide cancer affects more than 10 million people each year. This number is expected to increase by 2.4% by 2020 to 14 million each year. Worldwide approximately 22 million people are living with cancer and nearly 7 million people die. The most common cancers affecting the world include lung, breast, colon/rectum, stomach, liver, prostate, cervical, esophageal, and bladder.
This Kalorama Information report - The World Market for Cancer Therapeutics and Biotherapeutics - focuses on several segments for cancer treatment. The report covers both currently marketed and late stage development cancer products. Revenues for each current market segment were generated using dollar and unit sales for each product.
The following approaches to cancer therapeutics are covered in the report:
A Primary Research Effort
The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives. All market data pertains to the world market at the manufacturers’ level.
Coverage of the Most Recent Product and Trends
The base year for data was 2008. Historical data was provided for the years 2004 through 2007, with forecast data provided for 2009 through 2013. Compound annual growth rates (CAGRs) are provided for the 2004-2008, 2009-2013 and 2004-2013 periods for each industry segment covered. Competitive analysis is provided for the year 2008. The forecasted market analysis for 2009-2013 was based on probability of approval and sales of products in late stage development, product marketing, and demographic trends. Some of the trends that affected this market include the following:
As part of its comprehensive coverage, the following companies are profiled:
Sanofi, Eli, Schering Dominate Chemotherapy Marketplace, finds Kalorama Report
New York, August 30 2010 — The chemotherapy market is a well-established market and has maintained steady growth over the last decade. Worldwide there are hundreds of chemotherapy products that have been approved for cancer treatment, making this the largest area, in terms of available products, in the cancer therapeutics market. Despite new biologic drugs entering the market and the success of these products in treating cancer and other chronic illnesses, traditional therapies continue to be a first option for many cancer victims. Products such as gemcitabine, pemetrexed, and oxaliplatin are expected to continue to fuel this market as new applications for the use of these products are approved. However, the high side effect rate of many traditional chemotherapy products continues to be a primary concern for market growth and for many patients, is a deterring factor in treatment. Focusing on reducing side effects with chemotherapy will continue to be an advantageous position in new research and product development.
The chemotherapy market is a highly competitive area with hundreds of competitors - from large brand marketers to small niche, generic competitors. The increasing cancer incidence and ever changing patent status of products keeps this market growing. Sanofi-Aventis holds the number one position in this market with an estimated 2008 market share of 33.9%. Both of the company’s lead chemotherapy products, Eloxatin and Taxotere, have remained leaders in the market. Sales from Eloxatin were reported at $2 billion in 2008, while sales of Taxotere are increased to nearly $3 billion for 2008. In addition to the company’s currently marketed products, Sanofi-Aventis continues to enhance its cancer product line and has several promising research and development efforts in place. Additionally, new indications and dosage forms are in development for the company’s current products. Eli Lilly & Company’s presence in the chemotherapy market remains strong due to the success of its products Gemzar and Alimta. Strong performance of the company’s lead chemotherapy products are expected to enhance Eli Lilly’s market position. Schering-Plough continues to grow in market presence with its product Temodar, indicated for brain cancer and other products such as Caelyx securing a 8.8% market share.
About Kalorama InformationKalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook